Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
APGN Apexigen
1.680-0.130-7.18%
Close
01/31 16:00 ET
1.750+0.070+4.17%
Post Mkt Price 01/31 18:32 ET
High
1.830
Open
1.810
Turnover
393.83K
Low
1.600
Pre Close
1.810
Volume
230.20K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Apexigen (NASDAQ:APGN) Earns Buy Rating From Analysts at Roth Capital
Roth Capital started coverage on shares of Apexigen (NASDAQ:APGN – Get Rating) in a research report report published on Tuesday morning, The Fly reports. The brokerage issued a buy rating and a $15.0
Apexigen Price Target Announced at $15.00/Share by Roth Capital
Apexigen Price Target Announced at $15.00/Share by Roth Capital
Apexigen Announces Approximately $2.8M Private Placement Financing
Apexigen Announces $2.8M Private Placement Financing
Apexigen Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 01/24/2023 719.67% Roth Capital → $15 Reinstates → Buy 01/05/2023 337.16% EF Hutton → $8 Initiates Coverag
Roth Capital Reinstates Buy on Apexigen, Announces $15 Price Target
Roth Capital analyst Kumaraguru Raja reinstates Apexigen (NASDAQ:APGN) with a Buy and announces $15 price target.
BBBY, HEXO and ALLO Are Among Pre Market Gainers
Apexigen Resumed With a Buy at Roth Capital
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersJaguar Health (NASDAQ:JAGX) shares moved upwards by 7026.4% to $6.04 during Monday's pre-market session. The market value of their outstanding shares is at $912.8 million. Allarity Therapeutics
Why Pliant Therapeutics Shares Are Trading Higher By Around 49%; Here Are 20 Stocks Moving Premarket
Gainers Jeffs' Brands Ltd (NASDAQ:JFBR) rose 76.5% to $2.70 in pre-market trading after jumping 19% on Friday.Pliant Therapeutics, Inc. (NASDAQ:PLRX) rose 48.8% to $33.49 in pre-market trading after
Company Overview
More
Apexigen(formerly Brookline Capital Acquisition Corp.) is a clinical-stage biopharmaceutical company focused on developing innovative antibody therapies for the treatment of cancer with an immuno oncology focus. Apexigen has built a diversified pipeline of wholly owned and collaborative assets using its proprietary APXiMAB ? antibody discovery platform. The company's primary asset, Sotigalimab, is potentially the best-in-class and best-in-class CD40 agonist with unique epitope specificity and Fc receptor binding to achieve optimal therapeutic outcomes.
CEO： Dr. Xiaodong Yang, M.D.
Market： NASDAQ
Listing Date： 01/29/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet